Silencing of Cathepsin B suppresses the proliferation and invasion of endometrial cancer

Bao,Wei; Fan,Qiong; Luo,Xin; Cheng,Wei-Wei; Wang,Yu-Dong; Li,Zhu-Nan; Chen,Xin-Liang; Wu,Dan

doi:10.3892/or.2013.2496

Silencing of Cathepsin B suppresses the proliferation and invasion of endometrial cancer

Authors:
- Wei Bao
- Qiong Fan
- Xin Luo
- Wei-Wei Cheng
- Yu-Dong Wang
- Zhu-Nan Li
- Xin-Liang Chen
- Dan Wu
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, International Peace Maternity and Child Health Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200030, P.R. China, The Centre of Research Laboratory, International Peace Maternity and Child Health Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200030, P.R. China
Published online on: May 27, 2013 https://doi.org/10.3892/or.2013.2496
Pages: 723-730

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The molecular mechanism involved in the metastasis of endometrial cancer (EC) remains unclear. The lysosomal cysteine protease Cathepsin B has been implicated in the progression of various human tumors. In the present study, we assessed the expression of Cathepsin B and its functions in EC. Immunohistochemistry was used to examine Cathepsin B expression in 76 paraffin-embedded endometrial tumor tissues. Lentiviral packing short hairpin RNA (shRNA) was transfected into HEC-1A cells to build a stable Cathepsin B knockdown cell line. The cellular levels of Cathepsin B mRNA and protein were detected by real-time PCR and western immunoblotting. The functions of Cathepsin B in EC cells were measured by MTT, migration and invasion assays. In additon, tumorigenicity assays were established in nude mice to study tumor growth in vivo. The results of our study showed that Cathepsin B was overexpressed in EC tissues compared with normal endometrium and endometrial atypical hyperplasia. Depletion of Cathepsin B in vitro inhibited cell proliferation, migration and invasion. Tumor formation assays confirmed that suppression of Cathepsin B inhibited the proliferation potential of HEC-1A cells in vivo, demonstrated by lower proliferation rates. These results suggest that Cathepsin B may act as an oncogene in EC, with the potential to provide a new therapeutic target for treating endometrial malignancy.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
2	Abal M, Llaurado M, Doll A, et al: Molecular determinants of invasion in endometrial cancer. Clin Transl Oncol. 9:272–277. 2007. View Article : Google Scholar : PubMed/NCBI
3	Mylonas I, Makovitzky J, Richter DU, Jeschke U, Briese V and Friese K: Cathepsin D expression in normal, hyperplastic and malignant endometrial tissue: an immunohistochemical analysis. Acta Histochem. 105:245–252. 2003. View Article : Google Scholar : PubMed/NCBI
4	Aglund K, Rauvala M, Puistola U, et al: Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and the stage. Gynecol Oncol. 94:699–704. 2004. View Article : Google Scholar : PubMed/NCBI
5	Sanseverino F, Santopietro R, Torricelli M, et al: pRb2/p130 and VEGF expression in endometrial carcinoma in relation to angiogenesis and histopathologic tumor grade. Cancer Biol Ther. 5:84–88. 2006. View Article : Google Scholar : PubMed/NCBI
6	Santin AD, Diamandis EP, Bellone S, et al: Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer. Clin Cancer Res. 11:3320–3325. 2005. View Article : Google Scholar : PubMed/NCBI
7	Roshy S, Sloane BF and Moin K: Pericellular cathepsin B and malignant progression. Cancer Metastasis Rev. 22:271–286. 2003. View Article : Google Scholar : PubMed/NCBI
8	Nasu K, Kai K, Fujisawa K, Takai N, Nishida Y and Miyakawa I: Expression of cathepsin L in normal endometrium and endometrial cancer. Eur J Obstet Gynecol Reprod Biol. 99:102–105. 2001. View Article : Google Scholar : PubMed/NCBI
9	Vasiljeva O and Turk B: Dual contrasting roles of cysteine cathepsins in cancer progression: apoptosis versus tumour invasion. Biochimie. 90:380–386. 2008. View Article : Google Scholar : PubMed/NCBI
10	Sinha AA, Jamuar MP, Wilson MJ, Rozhin J and Sloane BF: Plasma membrane association of cathepsin B in human prostate cancer: biochemical and immunogold electron microscopic analysis. Prostate. 49:172–184. 2001. View Article : Google Scholar : PubMed/NCBI
11	Jedeszko C and Sloane BF: Cysteine cathepsins in human cancer. Biol Chem. 385:1017–1027. 2004. View Article : Google Scholar : PubMed/NCBI
12	Victor BC, Anbalagan A, Mohamed MM, Sloane BF and Cavallo-Medved D: Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion. Breast Cancer Res. 13:R1152011. View Article : Google Scholar : PubMed/NCBI
13	Chen Q, Fei J, Wu L, et al: Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients. Oncol Lett. 2:693–699. 2011.PubMed/NCBI
14	Talieri M, Papadopoulou S, Scorilas A, et al: Cathepsin B and cathepsin D expression in the progression of colorectal adenoma to carcinoma. Cancer Lett. 205:97–106. 2004. View Article : Google Scholar : PubMed/NCBI
15	Scorilas A, Fotiou S, Tsiambas E, et al: Determination of cathepsin B expression may offer additional prognostic information for ovarian cancer patients. Biol Chem. 383:1297–1303. 2002. View Article : Google Scholar : PubMed/NCBI
16	Devetzi M, Scorilas A, Tsiambas E, et al: Cathepsin B protein levels in endometrial cancer: potential value as a tumour biomarker. Gynecol Oncol. 112:531–536. 2009. View Article : Google Scholar : PubMed/NCBI
17	Creasman W: Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet. 105:1092009. View Article : Google Scholar : PubMed/NCBI
18	Wu D, Wang H, Li Z, et al: Cathepsin B may be a potential biomarker in cervical cancer. Histol Histopathol. 27:79–87. 2012.PubMed/NCBI
19	Kyo S, Sakaguchi J, Ohno S, et al: High Twist expression is involved in infiltrative endometrial cancer and affects patient survival. Hum Pathol. 37:431–438. 2006. View Article : Google Scholar : PubMed/NCBI
20	Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
21	Sato R, Jobo T and Kuramoto H: Parametrial spread is a prognostic factor in endometrial carcinoma. Eur J Gynaecol Oncol. 24:241–245. 2003.PubMed/NCBI
22	Jedinak A and Maliar T: Inhibitors of proteases as anticancer drugs. Neoplasma. 52:185–192. 2005.PubMed/NCBI
23	Hornebeck W, Emonard H, Monboisse JC and Bellon G: Matrix-directed regulation of pericellular proteolysis and tumor progression. Semin Cancer Biol. 12:231–241. 2002. View Article : Google Scholar : PubMed/NCBI
24	Bradley WH, Lima PH, Rodgers L, Blomquist CH and Downs LS: Endometrial carcinoma expresses an increased cathepsin B/D ratio. Gynecol Oncol. 108:84–89. 2008. View Article : Google Scholar : PubMed/NCBI
25	Gopinathan A, Denicola GM, Frese KK, et al: Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice. Gut. 61:877–884. 2012. View Article : Google Scholar : PubMed/NCBI
26	Nomura T and Katunuma N: Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. J Med Invest. 52:1–9. 2005. View Article : Google Scholar : PubMed/NCBI
27	Shiose Y, Ochi Y, Kuga H, Yamashita F and Hashida M: Relationship between drug release of DE-310, macromolecular prodrug of DX-8951f, and cathepsins activity in several tumors. Biol Pharm Bull. 30:2365–2370. 2007. View Article : Google Scholar : PubMed/NCBI
28	Sloane BF, Yan S, Podgorski I, et al: Cathepsin B and tumor proteolysis: contribution of the tumor microenvironment. Semin Cancer Biol. 15:149–157. 2005. View Article : Google Scholar : PubMed/NCBI
29	Vasiljeva O, Korovin M, Gajda M, et al: Reduced tumour cell proliferation and delayed development of high-grade mammary carcinomas in cathepsin B-deficient mice. Oncogene. 27:4191–4199. 2008. View Article : Google Scholar : PubMed/NCBI
30	van der Stappen JW, Williams AC, Maciewicz RA and Paraskeva C: Activation of cathepsin B, secreted by a colorectal cancer cell line requires low pH and is mediated by cathepsin D. Int J Cancer. 67:547–554. 1996.PubMed/NCBI
31	Skrzydlewska E, Sulkowska M, Koda M and Sulkowski S: Proteolytic-antiproteolytic balance and its regulation in carcinogenesis. World J Gastroenterol. 11:1251–1266. 2005. View Article : Google Scholar : PubMed/NCBI
32	Mason SD and Joyce JA: Proteolytic networks in cancer. Trends Cell Biol. 21:228–237. 2011. View Article : Google Scholar : PubMed/NCBI
33	Caglic D, Pungercar JR, Pejler G, Turk V and Turk B: Glycosaminoglycans facilitate procathepsin B activation through disruption of propeptide-mature enzyme interactions. J Biol Chem. 282:33076–33085. 2007. View Article : Google Scholar : PubMed/NCBI